Organon Is Ready To Launch And Makes The Case To Investors
Established Products Will Account For The Majority Of Revenues
Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.
You may also be interested in...
Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.
CEO Kevin Ali talked to Scrip about his plans for Organon, ahead of the spinout from Merck & Co. Women's health will be the top priority.
In June, the $6bn Organon business, including a healthy biosimilars operation, will begin trading, while Coherus BioSciences aims to file for biosimilar Lucentis with partners Formycon and Bioeq.